Pfizer – Gene Therapy Site-Preparedness

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire within unit

Memorial Deadline: Tuesday 7th, February 2023

External Deadline: Tuesday 14th, February 2023


PLEASE NOTE: Pfizer has extended the application due date to February 14, 2023.

This Request for Proposals (RFP) is for initiatives that span multiple rare disease areas. The International Pharmaceutical Federation (FIP) and Pfizer Global Medical Grants are collaborating to offer a new competitive grant opportunity focused on Pharmacy teams and the integration of gene therapy into the treatment armamentarium for patients with a Rare Disease. The focus is the roles of pharmacy in ensuring gene therapy site preparedness in the management of rare diseases, and then by sharing learnings and experiences more widely.

For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

More details can be found here.


Date RFP Issued: November 15, 2022

Geographic Scope: Global

Clinical Area: Gene Therapy- Rare Disease

Link to full RFP: Gene Therapy Site-Preparedness

Application Due Date: January 18, 2023

Specific Area of Interest: Projects that will be considered for support will focus on operationally preparing and/or optimizing Institutional Pharmacists for the integration of recombinant Adeno-Associated Virus (rAAV) gene therapy into the treatment armamentarium for patients with a Rare Disease.


Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: January 24, 2023